Associations of VEGFR2 rs2305948 polymorphism with long-term prognosis of myocardial infarction

   Aim. To evaluate the associations of VEGFR2 rs2305948 polymorphism with the occurrence of cardiovascular events during long-term follow-up in patients with myocardial infarction.

   Material and methods. The study included 218 patients with acute infarction (MI), mean age 57.7 ± 9.9 years (M ± SD). After clinical examination and preparation, patients urgently underwent coronary angiography followed by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). All patients underwent determination of the rs2305948 VEGFR2 allelic variant by polymerase chain reaction. The duration of long-term follow-up of these patients was 9 years (from 2015 to 2024).

   Results. It was determined that during long-term follow-up, patients with rs2305948 VEGFR (C/T and T/T), in contrast to patients with rs2305948 VEGFR (C/C), were more likely to experience cardiovascular death, recurrent acute coronary syndrome (ACS), recurrent revascularization and a combined end point (cardiovascular death, recurrent ACS, coronary stent/bypass thrombosis, acute ischemic cerebrovascular accident, repeated myocardial revascularization). Using multivariate analysis, it was determined that the occurrence of cardiovascular death during long-term follow-up is directly influenced by the Charlton comorbidity index (p < 0.001) and rs2305948 VEGFR2 (C/T and T/T) (p = 0.030). The onset of a combined endpoint is directly determined by the Charlton comorbidity index (p = 0.014) and rs2305948 VEGFR2 (C/T and T/T) (p = 0.034) and vice versa by subsequent outpatient treatment with high doses of statins (p < 0.001).

   Conclusions. The presence of rs2305948 VEGFR (C/T and T/T) in patients with MI increases the likelihood of cardiovascular death by 2.82 times and the combined endpoint by 2.10 times during long-term follow-up (9 years).

1. Nikitin Yu.P., Panin L.E., Voevoda M.I., Simonova G.I., Dushkin M.I., Ragino Yu.I., Nikolaev K.Yu., Ryabikov A.N., Denisova D.V., Tikhonov A.V., Shvarts Ya.Sh. Issues of atherogenesis. Novosibirsk: Rotaprint SNIIGGiMS, 2005. P. 372 (In Russ.)

2. Nikitin Yu.P., Nikolaev K.Yu., Ragino Yu.I., Malyutina S.K., Zhuravskaya E.Ya. Endothelial dysfunction, hypertension, atherosclerosis. Novosibirsk: SB RAS, 2014. P. 132. (In Russ.)

3. Abdel Hamid M., Bakhoum S.W., Sharaf Y., Sabry D., El-Gengehe A.T., Abdel-Latif A. Circulating endothelial cells and endothelial function predict major adverse cardiac events and early adverse left ventricular remodeling in patients with ST-segment elevation myocardial infarction. J. Interv. Cardiol., 2016; 29 (1): 89–98. doi: 10.1111/joic.12269

4. Nikolaev K.Yu., Urvantseva I.A., Batueva К.Yu., Apartsin К.A., Gorokhova А.V., Ganyukov V.I., Kochergin N.А., Zelenskaya Е.M., Lifshits G.I. Regional aspects of the gene polymorphism VЕGFR2 with coronary atherosclerosis in acute coronary syndrome. Russian Journal of Cardiology, 2017; (10): 61–65. (In Russ.). doi: 10.15829/1560-4071-2017-10-61-65

5. Hajer F., Hana S., Saoussen C., Abdelhak F., Nadia B., Ameni D., Habib G., Hassen B.A., Amel H.K. Genetic polymorphisms in VEGFA and VEGFR2 genes associated with coronary heart disease susceptibility and severity. Mol. Biol. Rep., 2023; 50 (12): 10169–10177. doi: 10.1007/s11033-023-08899-z

6. Liu D., Song J., Ji X., Liu Z., Cong M., Hu B. Association of genetic polymorphisms on VEGFA and VEGFR2 with risk of coronary heart disease. Medicine (Baltimore), 2016; 95 (19): e3413. doi: 10.1097/MD.0000000000003413

7. Zelenskaya E.M., Lifshits G.I., Nikolaev K.Y., Donirova O.S., Altayev V.D., Apartsin K.A., Voronina E.N., Protasov K.V., Sychev D.A. The frequency of the minor polymorphisms in the CYP2C19, VEGFR-2 genes, and clinical outcomes in russian and buryat patients with acute coronary syndrome. Genet. Test. Mol. Biomarkers, 2020; 24 (6): 338–342. doi: 10.1089/gtmb.2019.0216

8. Wang L., Ge H., Peng L., Wang B. A meta-analysis of the relationship between VEGFR2 polymorphisms and atherosclerotic cardiovascular diseases. Clin. Cardiol., 2019; 42 (10): 860–865. doi: 10.1002/clc.23233

9. Ahmed A.A., Amber K.I., Hadi N.R. The impact of kinase insert domain (KDR) gene polymorphism rs2305948 on clopidogrel resistance in Iraqi patients undergoing elective Percutaneous Coronary Intervention (PCI). Acta Inform. Med., 2020; 28 (3): 202–208. doi: 10.5455/aim.2020.28.202-208

10. Lungu C.N., Mehedinti M.C. Molecular motifs in vascular morphogenesis: vascular endothelial growth factor A (VEGFA) as the leading promoter of angiogenesis. Int. J. Mol. Sci., 2023; 24 (15): 12169. doi: 10.3390/ijms241512169

11. Jamaiyar A., Juguilon C., Wan W., Richardson D., Chinchilla S., Gadd J., Enrick M., Wang T., Mc-Cabe C., Wang Y., Kolz C., Clark A., Thodeti S., Ohanyan V., Dong F., Zhou B., Chilian W., Yin L. The essential role for endothelial cell sprouting in coronary collateral growth. J. Mol. Cell. Cardiol., 2022; 165: 158–171. doi: 10.1016/j.yjmcc.2022.01.005